Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Brain metastasis affects one third of patients with HER2-positive breast cancer after treatment with trastuzumab. Surgical resection and radiation therapy are often unsuccessful at accomplishing complete control of metastasis. Lapatinib is presumed to cross the blood-brain barrier, and exhibits clinical activities for treatment of HER2- positive breast cancer. A 43-year-old woman was treated for early breast carcinoma with total mastectomy, axillary lymph-node dissection, and adjuvant chemotherapy with cyclophosphamide plus doxorubicin. After the end of adjuvant trastuzumab ther- apy, she was diagnosed with panhypopituitarism due to pituitary metastasis. Surgical removal and whole brain radiation therapy were performed, but a portion of viable tumor remained. Only taking lapatinib, the size of the metastatic lesion began to shrink. Trastuzumab may have controlled the micro-metastasis of breast cancer, but it was unable to control its progression to the central nervous system. Lapatinib is a possible option for HER2-positive metastatic breast cancer patients with brain metas- tasis.
Abstract
Brain metastasis affects one third of patients with HER2-positive breast cancer after treatment with trastuzumab. Surgical resection and radiation therapy are often unsuccessful at accomplishing complete control of metastasis. Lapatinib is presumed to cross the blood-brain barrier, and exhibits clinical activities for treatment of HER2- positive breast cancer. A 43-year-old woman was treated for early breast carcinoma with total mastectomy, axillary lymph-node dissection, and adjuvant chemotherapy with cyclophosphamide plus doxorubicin. After the end of adjuvant trastuzumab ther- apy, she was diagnosed with panhypopituitarism due to pituitary metastasis. Surgical removal and whole brain radiation therapy were performed, but a portion of viable tumor remained. Only taking lapatinib, the size of the metastatic lesion began to shrink. Trastuzumab may have controlled the micro-metastasis of breast cancer, but it was unable to control its progression to the central nervous system. Lapatinib is a possible option for HER2-positive metastatic breast cancer patients with brain metas- tasis.
참고문헌 (15)
- Slamon DJ, "Human breast cancer : correlation of relapse and survival with amplification of the HER-2", neu oncogene, 1987, pp.235, 177~182
- Slamon DJ, "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2", N Engl J Med, 344, pp.783~792 (2001)
- Bendell JC, "Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma", Cancer, 97, pp.2972~2977 (2003)
- Stemmler HJ, "Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer", Breast, 15, pp.219~225 (2006)
- Pestalozzi BC, "Trastuzumab in CSF", J Clin Oncol, 18, pp.2349~2351 (2000)
- Komninos J, "Tumors metastatic to the pituitary gland : case report and literature review", J Clin Endocrinol Metab, 89, pp.574~580 (2004)
- Fassett DR, "Metastases to the pituitary gland", Neurosurg Focus, 16, pp.8~ (2004)
- Gsponer J, "Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients", Medicine(Baltimore), 78, pp.236~269 (1999)
- Rusnak DW, "The characterization of novel, dual ErbB-2", EGFR, tyrosine kinase inhibitors : potential therapy for cancer, 2001, pp.61, 7196~7203
- Geyer CE, "Lapatinib plus capecitabine for HER2-positive advanced breast cancer", N Engl J Med, 355, pp.2733~2743 (2006)
- Cameron D, "A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analyses", Breast Cancer Res Treat, 112, pp.533~543 (2008)
- Bachelot T, "Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer(LANDSCAPE) : a single-group phase 2 study", Lancet Oncol, 14, pp.64~71 (2013)
- Houck WA, "Clinical features of tumor metastasis to the pituitary", Cancer, 26, pp.656~659 (1970)
- Max MB, "Pituitary metastasis : incidence in cancer patients and clinical differentiation from pituitary adenoma", Neurology, 31, pp.998~1002 (1981)
- Taskar KS, "Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer", Pharm Res, 29, pp.770~781 (2012)